COVID-19 vaccine have been indicated to successfully decrease the hazard for symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection furthermore associated hospitalisations. To study the immune response to the Pfizer-BioNTech of SARS-CoV-2 vaccines. The study was conducted in Yarmouk and Tarmiyah Hospital from the September 2021 to the March 2022. A total of 120 randomized samples aged 18-80 years old. 30 samples of patients infected with corona they did not take the COVID-19 vaccine .90 people not infected with COVID -19received corona vaccines, have a vaccine); Assessment level of IgG in individuals that take, as follow, after 2 weeks from the first dose of vaccine, before the second dose directly, after one week from the second dose, and after 2 months from the second dose of Pfizer vaccine. The study determined conducted no significant differences between male and female individuals that take covid -19 vaccines, and shows no related in any chronic other diseases such as diabetic, hypertensions patients and cancer diseases. Assessment level of IgG in individuals that take Pfizer vaccine and control group showed a highly significant difference P-Value (0.00003) between individuals that take Pfizer vaccine and control group. There was a positive correlation when assessment level of IgG in individuals that take of Pfizer vaccine.